Table 4c.
In-patient ICU admission and investigations in Fibrotic and Non Fibrotic Subjects.
| No Fibrosis | Post Covid Fibrosis | P value (no. of observations) | OR (95% CI) unadjusted | OR (95% CI) adjusted | |
|---|---|---|---|---|---|
| Admitted to ICU | 61 (17.4%) | 23 (63.9%) | <0.001* (387) | 8.38 (4.02–17.46) | |
| Intubated | 38 (10.7%) | 22 (61.1%) | <0.001* (387) | 12.9 (6.09–27.31) | 3.48 (1.16–10.49) b |
| Duration intubated a (days) | 14 (7–34) | 27.5 (19–49) | 0.004* (387) | ||
| Peak CRPa (mg/L) | 130.5 (70–218) | 214 (122–379) | 0.001* (375) | ||
| Peak WBC a (109/L) | 9.4 (7.1–13.4) | 17.1 (11.9–21.3) | <0.001* (375) | 6.16 (2.8–13.5) c | 2.57 (0.85–7.79) b |
| Peak Ferritin a (μg/L) | 906 (526–1620) | 1250 (932–2735.5) | 0.036 *(145) | ||
| Peak D-Dimera (ng/ml) | 619 (310–2633) | 3026 (1530–5467) | 0.001 *(145) | ||
| Minimum Lymphocytesa (109/L) | 0.7 (0.5–1.0) | 0.5 (0.4–0.8) | 0.006* (375) | ||
| High risk Inpatient CXR | 136 (46.7%) | 29 (85.3%) | <0.001* (325) | 6.61 (2.49–17.6) | 3.31 (0.82–13.33) b |
| In patient CT scorea | 14 (11–19) | 21 (17–23) | 0.001 * (89) | ||
| High risk inpatient CT (score ≥18) | 21 (28%) | 9 (64.3%) | 0.008 * (89) | 4.63 (1.39–15.4) |
Data presented as Frequency (%) compared using Chi square test except.
a
Median (interquartile range) compared using Mann-Whitney U test * significant.
b
Adjusted for male sex, persistent breathlessness, myalgia, invasive ventilation, Peak WBC and high risk CXR during COVID-19 admission.
c
Unadjusted OR for Peak WBC ≥12 × 106/L.